Bedrocan, a Dutch company and European flagship in medical cannabis, will expand its production capacity with the creation of a new site already categorized GMP (Good Manufacturing Practices, GMP in English) for the cultivation and packaging of cannabis medicine in Denmark. The new facility will be located in Køge, 30 kilometers south of Copenhagen.
Respond to international demand
The main reason for Bedrocan’s expansion into Denmark is to better meet the growing international demand for its high quality medicinal cannabis products. Under the current legal framework in the Netherlands, Bedrocan products are only available through the Dutch Office for Medicinal Cannabis (OMC), which is part of the Ministry of Health.
Bedrocan hopes to significantly improve the availability of its products for patients around the world. In Denmark, Bedrocan will be able to do business directly with other commercial entities, in Europe and for export.
The new facility will comply with all relevant regulatory requirements (GACP and GMP). Products from this facility are initially intended to supply European medical cannabis markets. The facility will employ approximately 40 people and will be operational by the end of 2023.
The facility is beginning to produce some of Bedrocan’s currently known strains, such as the eponymous Bedrocan strain (a 22% THC Jack Herer) and Bediol, as well as a new high CBD strain. Dried cannabis products are presented grinded (not whole flowers) in small and large packages.
For the manufacture of cannabis extracts and isolates, it will also be possible to obtain whole plant cannabis from the Danish facility.